Webcasts: Corporate Presentation Webcast, January 9, 2012 at 11:30 a.m. (PT)
Intellicell™ Biosciences Ticker Symbol for Stocks: OTCQB: SVFC
For Investor Relations Questions & Answers: Phone: 212-249-3050
www.sec.gov - Link to Intellicell Bioscience's SEC ListingCorporate Summary
- Experienced management team in regenerative medicine
- Top tier scientific and medical advisory group
- Ultrasound based patent pending manufacturing process
- Addresses multiple medical treatment areas with significant unmet clinical needs such as osteoarthritis, gingival gum regeneration, sports medicine, and multiple sclerosis
- First autologous VFC process for enhanced cellular yields without culturing cells or using enzymatic digestion
Proven Management and Seasoned Board Of Directors
Intellicell™ BioSciences Corporate Profile:
IntelliCell™ BioSciences is a regenerative medicine company focused on the expanding regenerative medical markets. It has identified the technologies and laboratory process to target a portfolio of products and services in personalized medicine for the regenerative, preventative, and curative elements of age related disease states. The leading VFC autologous stem cell product candidates, treating osteoarthritis and gingival gum degeneration, are being planned for clinical trials in 2012 and 2013. More >
Intellicell™ Facts:
The IntelliCell™ technology process is based upon acquiring the vascular tissue, primarily capillaries, that surround fat tissue from the abdomen. The vascular tissue is a rich source of many autologous cell types that are being studied for use in regenerative medicine. IntelliCell™ has developed a novel process using ultrasound that results in a cellular composition which is called Stromal Vascular Cells or SVC. SVC is also referred to as stromal vascular fraction or SVF. Of particular interest to researchers around the world is the potential capability of this autologous cell population to have a significant role in regenerative medicine. More >
Intellicell™ Clinical Studies:
IntelliCell™ is focused on areas in medicine with high unmet clinical needs. Our planned clinical studies include autologous cellular treatments for osteoarthritis, gingival gum regeneration, sports medicine injuries, and multiple sclerosis. The Company is planning to work with well respected clinical investigators in the fields of orthopedics, orthodontics, and internal medicine. Our objective is to take a leadership role in the development of ethical and safe products for regenerative medicine. More >